Mankind Pharma Limited
NSE: MANKIND BSE: MANKIND
NSE
2,061.60
-32.30 (-1.54%)
Prev Close
2093.9
Open Price
2100
Volume
150,081
Today Low / High
2046.8 / 2120
52 WK Low / High
2048 / 2716.5
Range
1,959 - 2,165
BSE
2,055.95
-37.10 (-1.77%)
Prev Close
2093.05
Open Price
2087.75
Volume
4,394
Today Low / High
2050 / 2125.45
52 WK Low / High
2050 / 2726.75
Range
1,953 - 2,159
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2061.6 (target range: 1,959 - 2,165), reflecting a change of -32.3 (-1.54258%). On the BSE, it is listed at 2055.95 (target range: 1,953 - 2,159), showing a change of -37.1 (-1.77253%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
02 Feb
2,100.00
-1.87%
01 Feb
2,124.00
-1.42%
30 Jan
2,082.60
1.99%
29 Jan
2,107.00
-0.29%
28 Jan
2,106.60
0.49%
27 Jan
2,131.40
-1.75%
23 Jan
2,150.90
-2.01%
22 Jan
2,111.00
1.71%
21 Jan
2,124.30
-1.19%
20 Jan
2,112.00
0.58%
19 Jan
2,170.00
-2.43%
16 Jan
2,255.50
-3.55%
14 Jan
2,224.00
0.92%
13 Jan
2,220.00
-0.27%
12 Jan
2,201.50
1.04%
09 Jan
2,250.00
-2.19%
08 Jan
2,314.00
-2.28%
07 Jan
2,241.00
3.16%
06 Jan
2,205.00
1.62%
05 Jan
2,205.00
-0.45%
Mankind Pharma Limited Graph
Mankind Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Mankind Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,061.60, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2,055.95 | 2,076.51 | 1,868.86 - 2,284.16 |
| 2,097.07 | 1,677.66 - 2,516.48 | ||
| 2,117.63 | 1,482.34 - 2,752.92 | ||
| Bearish Scenario | 2,055.95 | 2,035.39 | 1,831.85 - 2,238.93 |
| 2,014.83 | 1,611.86 - 2,417.80 | ||
| 1,994.27 | 1,395.99 - 2,592.55 |
Overview of Mankind Pharma Limited
ISIN
INE634S01028
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
460,809
Market Cap
849,594,118,683
Last Dividend
2
Official Website
IPO Date
2023-05-09
DCF Diff
582.54
DCF
1,474
Financial Ratios Every Investor Needs
Stock Dividend of MANKIND
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-08 | August 08, 25 | 1 | 1 | 2025-08-08 | 2025-08-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 12,207.44 Cr | 3,489.04 Cr | 8,718.40 Cr | 0.7142 | 232.36 Cr | 2,718.05 Cr | 6,026.03 Cr | 1,990.96 Cr | 49.17 | 3,017.93 Cr | 0.1631 |
| 2024-03-31 | 10,334.77 Cr | 3,320.72 Cr | 7,014.05 Cr | 0.6787 | 25.45 Cr | 2,297.94 Cr | 4,086.76 Cr | 1,912.90 Cr | 47.75 | 2,809.47 Cr | 0.1851 |
| 2023-03-31 | 8,742.85 Cr | 5,354.49 Cr | 3,388.36 Cr | 0.3876 | 25.45 Cr | 1,095.09 Cr | 1,617.98 Cr | 1,281.86 Cr | 32.00 | 2,026.67 Cr | 0.1466 |
| 2022-03-31 | 7,781.56 Cr | 2,470.01 Cr | 5,311.55 Cr | 0.6826 | 2.04 Cr | 124.69 Cr | 1,861.30 Cr | 1,433.48 Cr | 35.78 | 2,146.95 Cr | 0.1842 |
| 2021-03-31 | 6,214.43 Cr | 1,824.98 Cr | 4,389.45 Cr | 0.7063 | 12.37 Cr | 74.88 Cr | 1,606.46 Cr | 1,265.43 Cr | 31.59 | 1,816.57 Cr | 0.2036 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 554.50 Cr | 27,759.53 Cr | 13,191.35 Cr | 14,332.3900 Cr | 8,511.45 Cr | 7,956.95 Cr | 2,093.71 Cr | 3,259.17 Cr | 0.00 Cr | 20.00 Cr | 351.09 Cr | 5,663.5600 Cr |
| 2024-03-31 | 382.01 Cr | 11,963.25 Cr | 2,387.47 Cr | 9,363.0881 Cr | 207.17 Cr | -174.84 Cr | 1,553.46 Cr | 3,138.69 Cr | 49.75 Cr | 22.96 Cr | -407.07 Cr | 2,119.7298 Cr |
| 2023-03-31 | 304.82 Cr | 9,715.45 Cr | 2,066.66 Cr | 7,435.2228 Cr | 170.37 Cr | -134.45 Cr | 1,498.46 Cr | 3,075.80 Cr | 26.37 Cr | 25.49 Cr | 372.45 Cr | 1,863.1362 Cr |
| 2022-03-31 | 302.53 Cr | 9,147.74 Cr | 2,831.43 Cr | 6,155.2290 Cr | 873.08 Cr | 570.54 Cr | 1,760.24 Cr | 2,389.59 Cr | 520.46 Cr | 20.15 Cr | -736.38 Cr | 2,623.4690 Cr |
| 2021-03-31 | 167.18 Cr | 6,372.63 Cr | 1,509.74 Cr | 4,722.0020 Cr | 240.66 Cr | 73.48 Cr | 1,183.54 Cr | 1,991.69 Cr | 422.78 Cr | 7.89 Cr | -1,627.56 Cr | 1,353.3980 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,413.3800 Cr | -12,692.3500 Cr | 10,232.5600 Cr | 1,952.5900 Cr | 21.8725 Cr | 403.8800 Cr | -460.7900 Cr | 1,990.9600 Cr | 7,378.2100 Cr | 0.0000 Cr | -220.7000 Cr |
| 2024-03-31 | 2,152.4450 Cr | -2,081.6903 Cr | 5.2656 Cr | 1,770.1082 Cr | 77.1868 Cr | 382.0075 Cr | -389.2112 Cr | 1,912.8967 Cr | 33.9638 Cr | 0.0000 Cr | -55.0030 Cr |
| 2023-03-31 | 1,813.3017 Cr | -1,054.1287 Cr | -739.7281 Cr | 952.5172 Cr | 21.7603 Cr | 304.8207 Cr | -832.0690 Cr | 1,281.8591 Cr | -695.2432 Cr | 0.0000 Cr | 261.7799 Cr |
| 2022-03-31 | 919.7760 Cr | -1,369.1430 Cr | 604.6200 Cr | -1,425.7470 Cr | 155.7310 Cr | 283.0590 Cr | -2,345.5230 Cr | 1,974.5990 Cr | 624.2460 Cr | 0.0000 Cr | -576.7000 Cr |
| 2021-03-31 | 1,137.2440 Cr | -1,222.2110 Cr | -7.8110 Cr | 824.9280 Cr | -92.4030 Cr | 127.3280 Cr | -312.3160 Cr | 1,691.6110 Cr | 0.2670 Cr | 0.0000 Cr | -284.4030 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 3,697.16 Cr | 2,109.17 Cr | 1,587.99 Cr | 0.4295 | 699.51 Cr | 511.51 Cr | 12.39 | 1,013.20 Cr | 0.1384 |
| 2025-06-30 | 3,570.35 Cr | 1,053.59 Cr | 2,516.76 Cr | 0.7049 | 628.09 Cr | 438.32 Cr | 10.62 | 929.82 Cr | 0.1228 |
| 2025-03-31 | 3,079.37 Cr | 875.38 Cr | 2,203.99 Cr | 0.7157 | 1,488.19 Cr | 420.77 Cr | 10.31 | 607.63 Cr | 0.1366 |
| 2024-12-31 | 3,230.00 Cr | 935.22 Cr | 2,294.78 Cr | 0.7105 | 637.50 Cr | 380.23 Cr | 9.45 | 910.56 Cr | 0.1177 |
| 2024-09-30 | 3,076.51 Cr | 1,626.94 Cr | 1,449.57 Cr | 0.4712 | 744.42 Cr | 653.47 Cr | 16.31 | 962.04 Cr | 0.2124 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 559.28 Cr | 2,545.36 Cr | 3,104.64 Cr | 1,904.24 Cr | 1,971.76 Cr | 8,112.14 Cr | 3,319.83 Cr | 28,813.25 Cr | 13,284.55 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 2,524.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -14,568.18 Cr |
| 2025-03-31 | 554.50 Cr | 1,690.84 Cr | 2,245.34 Cr | 1,538.34 Cr | 2,093.71 Cr | 6,988.27 Cr | 3,259.17 Cr | 27,759.53 Cr | 13,191.35 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 4,726.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -10,789.30 Cr |
| 2024-09-30 | 1,192.58 Cr | 3,534.16 Cr | 4,726.74 Cr | 1,275.42 Cr | 1,678.85 Cr | 8,536.75 Cr | 3,140.48 Cr | 13,982.25 Cr | 3,192.95 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 438.32 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 420.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 380.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 653.47 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 536.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,622.90 | ₹3,893,880,722,813.00 | ₹1,845,955.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,940.00 | ₹1,576,883,365,200.00 | ₹155,426.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,950.60 | ₹1,337,062,555,264.00 | ₹172,937.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,179.80 | ₹982,263,950,562.00 | ₹685,278.00 |
| Lupin Limited | LUPIN | ₹2,098.40 | ₹958,547,021,600.00 | ₹359,059.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹872.30 | ₹877,737,909,477.00 | ₹267,288.00 |
| Mankind Pharma Limited | MANKIND | ₹2,061.80 | ₹851,121,497,450.00 | ₹150,031.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,163.20 | ₹675,588,447,874.00 | ₹538,899.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,456.00 | ₹652,346,640,000.00 | ₹40,063.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,883.80 | ₹531,609,883,994.00 | ₹1,003,955.00 |
| Laurus Labs Limited | LAURUSLABS | ₹936.90 | ₹505,791,631,676.00 | ₹1,284,238.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,451.00 | ₹368,124,820,318.00 | ₹222,987.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,773.40 | ₹346,496,459,602.00 | ₹59,486.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,855.60 | ₹297,703,186,000.00 | ₹116,169.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,462.40 | ₹277,230,882,496.00 | ₹74,252.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,546.00 | ₹213,650,000,000.00 | ₹2,018.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,301.70 | ₹211,516,056,387.00 | ₹448,916.00 |
| Eris Lifesciences Limited | ERIS | ₹1,366.60 | ₹186,154,003,241.00 | ₹17,511.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,024.00 | ₹167,096,474,336.00 | ₹23,750.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹770.25 | ₹151,402,746,261.00 | ₹20,620.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹940.85 | ₹149,002,177,406.00 | ₹53,210.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹819.55 | ₹146,789,493,959.00 | ₹190,327.00 |
| Cohance Lifesciences Limited | COHANCE | ₹362.45 | ₹138,661,459,893.00 | ₹258,436.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,772.90 | ₹134,761,137,359.00 | ₹24,342.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹544.90 | ₹132,230,183,348.00 | ₹224,495.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹909.65 | ₹111,646,802,400.00 | ₹47,371.00 |
| Viyash Scientific Limited | VIYASH | ₹200.60 | ₹87,502,835,135.00 | ₹224,229.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,213.50 | ₹86,540,878,057.00 | ₹7,268.00 |
| Strides Pharma Science Limited | STAR | ₹820.20 | ₹75,600,060,023.00 | ₹297,983.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹773.95 | ₹70,156,473,191.00 | ₹227,820.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹429.60 | ₹65,772,644,117.00 | ₹99,727.00 |
| FDC Limited | FDC | ₹370.25 | ₹60,280,433,601.00 | ₹23,831.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹273.60 | ₹53,511,184,858.00 | ₹263,821.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹130.73 | ₹42,424,707,199.00 | ₹1,250,684.00 |
| Innova Captab Limited | INNOVACAP | ₹692.20 | ₹39,611,095,854.00 | ₹15,986.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹377.40 | ₹34,445,298,000.00 | ₹38,711.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹314.25 | ₹34,242,334,526.00 | ₹21,638.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹665.00 | ₹33,728,204,825.00 | ₹18,906.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,977.00 | ₹32,697,632,655.00 | ₹7,379.00 |
| Suven Life Sciences Limited | SUVEN | ₹133.76 | ₹30,426,922,240.00 | ₹146,830.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹295.00 | ₹29,583,339,270.00 | ₹24,451.00 |
Key Executives
Chief Scientific Officer (Research Centre)
Anil Kumar
Gender: Not Specified
Year Born: 1953
Chief Operating Officer
Arjun Juneja
Gender: male
Year Born: 1986
Chief Financial Officer
Ashutosh Dhawan
Gender: male
Year Born: 1968
Director of Technology
Chanakya Juneja
Gender: male
Year Born:
Senior President & Group Chief Information Officer
Pramod Gokhale
Gender: male
Year Born: 1971
Director of Finance, Human Resources & Admin
Prem Kumar Arora
Gender: male
Year Born: 1947
Vice Chairman & MD
Rajeev Juneja
Gender: male
Year Born: 1965
Whole-Time Director & Executive Chairman
Ramesh C. Juneja
Gender: male
Year Born: 1955
Whole-Time Director
Satish Kumar Sharma
Gender: male
Year Born: 1973
Chief Executive Officer & Whole-Time Director
Sheetal Arora
Gender: male
Year Born: 1975
FAQs about Mankind Pharma Limited
Who is the CEO of the company?
The CEO is Sheetal Arora.
What is the current market price of the stock?
The current price is ₹2,058.10.
What is the 52-week price range?
The range is ₹2048-2716.5.
What is the market capitalization of the company?
The market capitalization is ₹84,959.41 crores.
What is the dividend yield?
The dividend yield is 0.05%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 48.52.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Mankind Pharma Limited (ISIN: INE634S01028) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹84,959.41 crores and an average daily volume of 460,809 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹2.